Under the selective pressure of therapy, HIV-1 protease mutants resistant to inhibitors evolve to confer drug resistance. Such mutations can impact both the dynamics and structures of the bound and unbound forms of the enzyme. Flap+ is a multidrug-resistant variant of HIV-1 protease with a combination of primary and secondary resistance mutations (L10I, G48V, I54V, V82A) and a strikingly altered thermodynamic profile for darunavir (DRV) binding relative to the wild-type protease. We elucidated the impact of these mutations on protein dynamics in the DRV-bound state using molecular dynamics simulations and NMR relaxation experiments. Both methods concur in that the conformational ensemble and dynamics of protease are impacted by the drug res...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in t...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...
Under the selective pressure of therapy, HIV-1 protease mutants resistant to inhibitors evolve to co...
*S Supporting Information ABSTRACT: Under the selective pressure of therapy, HIV-1 protease mutants ...
The protease from type I human immunodeficiency virus (HIV-1 ) is a critical drug target against whi...
Enzyme targets in rapidly replicating systems, such as retroviruses, commonly respond to drug-select...
The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional lon...
The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional lon...
<div><p>The PR20 HIV-1 protease, a variant with 20 mutations, exhibits high levels of multi-drug res...
ABSTRACT: HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
Drug resistance to HIV-1 protease involves the accumulation of multiple mutations in the protein...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in t...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...
Under the selective pressure of therapy, HIV-1 protease mutants resistant to inhibitors evolve to co...
*S Supporting Information ABSTRACT: Under the selective pressure of therapy, HIV-1 protease mutants ...
The protease from type I human immunodeficiency virus (HIV-1 ) is a critical drug target against whi...
Enzyme targets in rapidly replicating systems, such as retroviruses, commonly respond to drug-select...
The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional lon...
The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional lon...
<div><p>The PR20 HIV-1 protease, a variant with 20 mutations, exhibits high levels of multi-drug res...
ABSTRACT: HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
Drug resistance to HIV-1 protease involves the accumulation of multiple mutations in the protein...
HIV-1 protease is responsible for the cleavage of 12 nonhomologous sites within the Gag and Gag-Pro-...
HIV-1 protease inhibitors are part of the highly active antiretroviral therapy effectively used in t...
Drug resistance continues to be a growing global problem. The efficacy of small molecule inhibitors ...